Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial) [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating the efficacy, safety, and pharmacokinetics of Debio 4326 for central precocious puberty is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• Debio 4326

Snippet

Sponsor: Debiopharm International SA | Conditions: Central Precocious Puberty | Phase 3 | Status: ACTIVE_NOT_RECRUITING